ASX:CSL 22 December 2025 - 25 January 2026

CSL shares closed up 0.7% at A$179.62 on Friday ahead of the Australia Day market holiday. The ASX cash market will be shut Monday and reopen Tuesday. CSL will report half-year results and announce an interim dividend on Feb. 11. The S&P/ASX 200 rose 0.13% to 8,860.1, while traders increased bets on a February rate hike.

CSL shares rose 0.1% to A$176.70 Tuesday after RBC Capital Markets upgraded the stock, despite the ASX 200 falling 0.66%. The move follows a 36% drop in CSL’s share price over the past year and comes ahead of its Feb. 11 half-year results. RBC cited competition and weak flu vaccine demand as near-term risks. CSL last cut its 2026 revenue and profit growth forecasts in October and delayed its Seqirus spin-off.

CSL (ASX:CSL) closed Friday at A$175.53, up 0.14%, after filing in the U.S. to register up to 100 million American depositary shares. Around 1.07 million shares changed hands, with prices ranging from A$174.35 to A$176.07. Investors await CSL’s half-year results on Feb. 11 for updates on plasma therapies and vaccines.

CSL shares closed down 0.1% at A$174.29 on Friday after a two-day rise, with about 494,000 shares traded. A regulatory filing showed 34,261 employee share rights lapsed on Jan. 7 following staff departures. Investors are now focused on CSL’s half-year results and interim dividend announcement due Feb. 11. The ASX200 slipped 3 points to 8,716.

CSL closed at A$171.96 in Sydney, down 0.4%, near its 52-week low. The U.S.-traded ADR ended at $57.51, off 0.16%, in light trading. Investors await Australia’s CPI data on Jan. 7 and CSL’s half-year results on Feb. 11. The stock remains under pressure after last year’s guidance cut and canceled Seqirus spinoff.

CSL Limited shares closed at A$171.48 on 24 December 2025, down 2.38%, near their 52-week low of A$168.00. The company delayed the spin-off of its Seqirus vaccine arm and cut its FY26 outlook after a sharper-than-expected drop in US flu vaccination rates. Market value stands at about A$85.5 billion. Shares are down roughly 39% over the past year.

CSL Limited shares closed at A$176.31 on 22 December 2025, up 0.7% for the day but down 37.6% for the year. The company reported buying back 65,217 shares on 17 December, bringing its total buyback to about A$588 million as it targets up to A$750 million by June 2026. Investors remain focused on ongoing restructuring and uncertainty in the Seqirus vaccine unit.